Table 2.
Description and composition of the bivalent and quadrivalent HPV-L1 vaccines in human clinical trials
| Gardasil® | Cervarix™ | |
|---|---|---|
| 1. Company | Merck & Co | GlaxoSmithKline |
| 2. Vaccine formulation | VLP derived from HPV 6, 11, 16 and 18 | VLPs derived from HPV 16 and 18 |
| 3. Composition | Produced in a yeast system | Produced in an insect-cell system |
| 4. Route of administration | Intramuscular | Intramuscular |
| 5. Dose schedule | three-dose regime 0, 2, and 6 months | three-dose regime 0, 1, and 6 months |
| 6. Dosages | 0.5 mL (containing 20 μg HPV6, 40 μg HPV11, 40 μg HPV16 and 20 μg HPV18 VLP | 0.5 mL (containing 20 μg HPV16 and 20 μg HPV18 |
| 7. Adjuvant | 225 μg of aluminium hydroxyphosphate sulphate (alum) | 50 μg of aluminium hydroxide with 50 μg of AS04 |
| 8. Current analysis of vaccine | Safe, well tolerated and 100% efficacious | Safe, well tolerated and 100% efficacious |
| 9. Sustained efficacy | Effective through 5 yrsa | Effective through 4.5 yrsb |
| 10. Licensed for public use | >60 countries | Australia (women ≤45 yrs) |